Clinical trial NCT01028248 (phase 1, status: completed)
Conditions: central retinal vein occlusion
ICD codes: H34.8132, H34.8131, H34.8111, H34.8121, H34.8191, H34.8112, H34.8122
Drugs: ranibizumab (lucentis)
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age > 18 years

          -  Clinical evidence of perfused central retinal vein occlusion. A central retinal vein
             occlusion (CRVO) is defined as an eye that has retinal hemorrhages and a dilated
             retinal venous system in all 4 quadrants. Other evidence of a CRVO may include
             telangiectatic capillary bed and collateral vessels at the optic nerve head.

          -  Central macular edema present on clinical examination and OCT testing with a central
             point thickness and/or central 1mm subfield thickness > 250 microns.

          -  Visual acuity score greater than or equal to 19 letters (20/400) and less than or
             equal to 73 letters (20/40) by the ETDRS visual acuity protocol.

          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT
             testing and retinal photography

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women
             not using adequate contraception.

          -  Participation in another ocular investigation or trial simultaneously

          -  Uncontrolled hypertension

          -  Any condition that, in the opinion of the investigator, would preclude participation
             in the study (e.g. chronic alcoholism, drug abuse)

          -  Significant diabetic retinopathy (greater than moderate NPDR) or macular edema
             associated with diabetic retinopathy

          -  Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be
             contributing to the macular edema

          -  An eye that, in the investigator's opinion, has no chance of improving in visual
             acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or
             geographic atrophy)

          -  Presence of another ocular condition that may affect the visual acuity or macular
             edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)

          -  Evidence of neovascularization of the iris or retina (presence of ischemic CRVO)

          -  Evidence of central atrophy or fibrosis in the study eye

          -  Presence of substantial cataract, one that might decrease the vision by 3 or more
             lines of vision at sometime during the study.

          -  History of grid/focal laser or panretinal laser in the study eye

          -  History of vitreous surgery in the study eye

          -  History of use of intravitreal, peribulbar, or retrobulbar steroids within six months
             of the study.

          -  History of cataract surgery within 6 months of enrollment.

          -  History of YAG capsulotomy within 2 months of the surgery.

          -  Visual acuity <20/400 in the fellow eye

          -  Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.

          -  History of cerebral vascular accident or myocardial infarction within 3 months prior
             to Day 0.